<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8188">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03000348</url>
  </required_header>
  <id_info>
    <org_study_id>NBTCS02</org_study_id>
    <nct_id>NCT03000348</nct_id>
  </id_info>
  <brief_title>A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations</brief_title>
  <acronym>CARE-CF1</acronym>
  <official_title>A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Investigating the Optimal Dose Regimen, Efficacy, and Safety of Adding Oral Cysteamine in Adult Patients Being Treated for an Exacerbation of CF-associated Lung Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovaBiotics Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agility Clinical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>PSR Group B.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NovaBiotics Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the use of cysteamine in the treatment of adults with Cystic
      Fibrosis who are experiencing an exacerbation of CF-associated lung disease. There are six
      different potential dosing regimens, including one that is placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, double-blind, randomized, placebo-controlled, 6-arm study to
      investigate the optimal dose regimen, efficacy, and safety of cysteamine in the treatment of
      adult patients with CF who are experiencing an exacerbation of CF-associated lung disease.
      Patients will be screened for the study and eligible patients will be randomized to receive
      either cysteamine or placebo as add-on therapy to their standard of care treatment for
      CF-associated lung disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in CFRSD-CRISS</measure>
    <time_frame>Baseline through Day 21/End of Study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in CFQ-R</measure>
    <time_frame>Baseline through Day 21/End of Study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Jarad and Sequeiros Symptom Score Questionnaire</measure>
    <time_frame>Baseline through Day 21/End of Study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in sputum bacterial load</measure>
    <time_frame>Baseline through Day 21/End of Study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Global Assessment of Exacerbation outcome</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability assessed by the number of subjects with Adverse Events</measure>
    <time_frame>Baseline through Day 21/End of Study</time_frame>
    <description>Assessed by variables such as adverse events (AEs), laboratory assessments, physical examinations, and vital signs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in neutrophil elastase levels</measure>
    <time_frame>Baseline through Day 21/End of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sputum IL8</measure>
    <time_frame>Baseline through Day 21/End of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FEV1</measure>
    <time_frame>Baseline through Day 21/End of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Weight</measure>
    <time_frame>Baseline through Day 21/End of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in C-Reactive Protein</measure>
    <time_frame>Baseline through Day 21/End of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood leukocyte count</measure>
    <time_frame>Baseline through Day 21/End of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of blood cysteamine levels</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of sputum cysteamine levels</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>High Dose, Once per day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient takes one oral dose of Cysteamine (high dose) per day, in the morning. The patient takes two oral placebo doses, one at mid-day and one in the evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose, Twice per day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient takes two oral doses of Cysteamine (high dose) per day, one in the morning and one in the evening. The patient takes one oral placebo dose, at mid-day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose, Three times per day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient takes three oral doses of Cysteamine (high dose) per day, one in the morning, one at mid-day and one in the evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient takes three oral doses of placebo, one in the morning, one at mid-day and one in the evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose, Three times per day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient takes three oral doses of Cysteamine (low dose) per day, one in the morning, one at mid-day and one in the evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid-Range Dose, Three times per day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient takes three oral doses of Cysteamine (mid-range dose) per day, one in the morning, one at mid-day and one in the evening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cysteamine</intervention_name>
    <description>Oral Cysteamine Capsule</description>
    <arm_group_label>High Dose, Once per day</arm_group_label>
    <arm_group_label>High Dose, Twice per day</arm_group_label>
    <arm_group_label>High Dose, Three times per day</arm_group_label>
    <arm_group_label>Low Dose, Three times per day</arm_group_label>
    <arm_group_label>Mid-Range Dose, Three times per day</arm_group_label>
    <other_name>Lynovex</other_name>
    <other_name>NM001</other_name>
    <other_name>Lynovex Oral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Capsule</intervention_name>
    <description>Placebo Oral Capsule</description>
    <arm_group_label>High Dose, Once per day</arm_group_label>
    <arm_group_label>High Dose, Twice per day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Low Dose, Three times per day</arm_group_label>
    <arm_group_label>Mid-Range Dose, Three times per day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. CF-associated lung disease with documented history of chronic infection with
             Gram-negative organism(s)

          2. Established patient of the Principal Investigator's CF Multi Disciplinary Team (MDT)

          3. Age ≥18 years

          4. Weight &gt;40 kg

          5. FEV1 &gt;30% of predicted within the 6 months prior to study exacerbation

          6. At the baseline visit: experiencing a new exacerbation of CF-associated lung disease
             (based on Investigator assessment of ≥4 symptoms present on the Fuchs' criteria)
             requiring treatment that includes an aminoglycoside antibiotic

          7. Women of childbearing potential (not surgically sterile or 2 years postmenopausal)
             and men with a female partner of childbearing potential must use a medically accepted
             method of contraception and must agree to continue use of this method for the
             duration of the study and for 30 days after participation in the study. Acceptable
             methods of contraception for men and women include abstinence, barrier method (condom
             or diaphragm) with spermicide, intrauterine device (IUD), vasectomy in conjunction
             with barrier method, or steroidal contraceptive (oral, transdermal, implanted,
             injected) in conjunction with a barrier method.

          8. Willing and able to comply with all protocol requirements and procedures, including
             induction of sputum, if necessary

          9. Willing and able to provide signed and dated informed consent

        Exclusion Criteria:

          1. Hypersensitive to cysteamine or to any of the excipients

          2. Hypersensitive to penicillamine

          3. Transplant recipient

          4. Participation in any other interventional clinical research study (participation in
             observational studies is not exclusionary) within 30 days of Baseline (Day 0), and
             any planned participation in an interventional clinical research study for the
             duration of this study

          5. If female, pregnancy, planned pregnancy, or breast-feeding

          6. Any other significant disease/disorder which, in the Investigator's opinion, either
             puts the patient at risk due to study participation, or may influence the results of
             the study or the patient's ability to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Agility Clinical</last_name>
    <email>LYNOVEX-CARE-CF1@agility-clinical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deborah O'Neil, PhD</last_name>
    <phone>++44 (0) 1224 711377</phone>
    <email>deborah@novabiotics.co.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner University of Arizona Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Ryan, RRT</last_name>
      <phone>520-626-3125</phone>
      <email>Elizabeth.ryan@email.arizona.edu</email>
    </contact>
    <contact_backup>
      <last_name>Osmara Molina de Rodriguez, MS</last_name>
      <phone>520-626-3910</phone>
      <email>omolina@email.arizona.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Cori Daines, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Francisco Critical Care Medical Group California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna von Bakonyi</last_name>
      <phone>415-600-1107</phone>
      <email>vonBakA@cpmcri.org</email>
    </contact>
    <investigator>
      <last_name>Ryan Dougherty, MD FCCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noni Graham</last_name>
      <phone>352-294-5195</phone>
      <email>noni.graham@medicine.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Jorge Lascano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Florida Pulmonary</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bert Kesser</last_name>
      <phone>407-841-1100</phone>
      <phone_ext>118</phone_ext>
      <email>bkesser@cfpulmonary.com</email>
    </contact>
    <contact_backup>
      <last_name>Billy Fortson</last_name>
      <phone>407-841-1100</phone>
      <phone_ext>173</phone_ext>
      <email>bfortson@cfpulmonary.com</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel T. Layish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katharine Mokhiber, BS, RN</last_name>
      <phone>518-262-6608</phone>
      <email>mokhibk@mail.amc.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elham Alqudah, CRC</last_name>
      <phone>614-722-6842</phone>
      <email>Elham.alqudah@nationwidechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Clinical Research Services</last_name>
      <phone>614.722.2650</phone>
    </contact_backup>
    <investigator>
      <last_name>Benjamin Kopp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy Clark, BSN, RN</last_name>
      <phone>304-293-5264</phone>
      <email>tclark@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Kathryn Moffett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Medical College of Wisconsin/Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Hubertz</last_name>
      <phone>414-955-7019</phone>
      <email>ehubertz@mcw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ashley Wuerl</last_name>
      <phone>(414) 955-7036</phone>
      <email>awuerl@mcw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rose Franco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie Biller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Padiatrico Bambino Gesu Centro Fibrosi Cistica</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenza Lucidi</last_name>
      <phone>0039 06 6859 2045</phone>
      <email>vincenzina.lucidi@opbg.net</email>
    </contact>
    <contact_backup>
      <last_name>Enza Montemitro</last_name>
      <email>enza.montemitro@opbg.net</email>
    </contact_backup>
    <investigator>
      <last_name>Vincenza Lucidi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enza Montemitro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrato di Verona Borgo Trento Centro Fibrosi Cistica</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sonia Volpi, MD</last_name>
      <phone>0039 045 812 3025</phone>
      <email>sonia.volpi@ospedaleuniverona.it</email>
    </contact>
    <contact_backup>
      <last_name>Marianna Passiu</last_name>
      <email>marianna.passiu@ospedaleuniverona.it</email>
    </contact_backup>
    <investigator>
      <last_name>Sonia Volpi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Spinelli</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graham Devereux, MD, PhD</last_name>
      <phone>0044 1224 438 476</phone>
      <email>graham.devereux@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Kairen Griffiths, RGN MSc</last_name>
      <phone>0044 1224 551 228</phone>
      <email>kairen.griffiths@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Graham Devereux, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital Scottish Adult Cystic Fibrosis Service</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Fardon</last_name>
      <phone>0044 1382 496 578</phone>
      <email>tom.fardon@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Tom Fardon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western General Hospital Edinburgh, CF Adults / CF Unit</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 3HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Rodgers, MD</last_name>
      <phone>0044 1315 372 348</phone>
      <email>Helen.Rodgers@nhslothian.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Helen Rodgers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHS GGC</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gordon Macgregor</last_name>
      <phone>0044 1414 516 094/6095</phone>
      <email>gordon.macgregor@ggc.scot.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Margaret McFadden</last_name>
      <phone>0044 1412 327 600</phone>
      <email>Margaret.mcfadden@ggc.scot.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Gordon Macgregor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary Adult CF Centre</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Doe</last_name>
      <email>Simon.Doe@nuth.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca Johnson</last_name>
    </contact_backup>
    <investigator>
      <last_name>Simon Doe</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen Bourke</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norfolk</city>
        <zip>NR47UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Wilson</last_name>
    </contact>
    <contact_backup>
      <last_name>Carla Holloway</last_name>
    </contact_backup>
    <investigator>
      <last_name>Andrew Wilson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.novabiotics.co.uk/</url>
    <description>NovaBiotics Website</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 9, 2017</lastchanged_date>
  <firstreceived_date>December 11, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exacerbation</keyword>
  <keyword>CF</keyword>
  <keyword>Lung disease</keyword>
  <keyword>Lung infection</keyword>
  <keyword>Gram negative</keyword>
  <keyword>Bacterial Infection</keyword>
  <keyword>pneumonia</keyword>
  <keyword>bronchitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cysteamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
